Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

curred clinical site start up costs for our three co-therapy trials in the U.K. and our Phase II sarcoma clinical trial in the U.S. During the nine month period ending September 30, 2006, we incurred direct patient costs in four ongoing clinical trials along with clinical site start up costs associated with our U.S. recurrent malignant glioma and U.K. Phase Ia combination REOLYSIN(R)/radiation therapy trials.

We expect our clinical trial expenses will continue to increase for the remainder of 2007 compared to 2006 as we continue patient enrollment and expand our clinical trial program to include other trial sites and other studies.

Pre-Clinical Trial Expenses and Research Collaborations

2007 2006

$ $

-------------------------------------------------------------------------

Research collaboration expenses 694,315 634,199

Pre-clinical trial expenses 37,130 57,354

-------------------------------------------------------------------------

Pre-clinical trial expenses and

research collaborations 731,445 691,553

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the nine month period ending September 30, 2007, our research collaboration expenses were $694,315 compared to $634,199 for the nine month period ending September 30, 2006. Our research collaboration activity continues to focus on the interaction of the immune system and the reovirus, the use of the reovirus as a co-therapy with existing chemotherapeutics, the use of new RAS active viruses as potential therapeutics, and to investigate new uses of the reovirus as a therapeutic.

For the remainder of 2007, we still ex
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 VG Life Sciences, Inc., (OTCQB: ... and infectious diseases, announced that the U.S. Patent ... new composition of matter patent covering methods for ... CLIP. U.S. Patent No. 8957031 ... Sciences, VG1177, a synthetic peptide which has the ...
(Date:3/1/2015)... UK (PRWEB) March 01, 2015 ... partnership agreement for quality market research promotion on ... sell research reports worked out by DataGroup Booksellers. ... at Market Publishers Ltd, commented on the recent ... have DataGroup Booksellers in our team of publishers. ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... COLUMBIA, Md. (PRWEB) February 27, 2015 ... Unified Chromatography system (Nexera UC) can sequentially analyze ... chromatographic separation combined with high-sensitivity detection of targets ... system is designed to fulfill the measurement requirements ... pesticides in food products, drug delivery and search ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... and inflammatory diseases, today,announced that the U.S. ... its,Investigational New Drug (IND) application for its ... ), ENMD-2076 is a novel, ...
... Cinpathogen, through its,partnership in the Fudan-Cinpathogen Clinical and ... consulting,services to Shanghai area hospitals. For the past ... the Center has diagnosed and characterized over 3000,cases ... area,hospitals and colleagues at Fudan University, the University ...
... N.C., Jan. 3 Chimerix, Inc., a,biotechnology company ... Frazer, M.B., Ch.B., FRCA, FFPM has joined the,company ... Chimerix, Dr. Frazer served as the Chief Medical,Officer ... Medical) where he was responsible for the design ...
Cached Biology Technology:EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 2EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... head impact injury are an interesting scientific question. Professor ... for Biomechanics and Mechanobiology of the Ministry of Education, ... and the School of Materials Science and Engineering, Wuhan ... After 3 years of innovative research, they are making ...
... to achieve goals set by the federal government for reducing ... need to eliminate an average of 64 excess calories per ... American Journal of Preventive Medicine . This reduction could ... both. Without this reduction, the authors predict that the average ...
... Ill. -- Researchers have determined that bacteria are present ... the common belief that normal urine is sterile. These ... Journal of Clinical Microbiology by researchers at ... "Doctors have been trained to believe that urine is ...
Cached Biology News:Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2How many calories does it take to reach childhood obesity prevention goals? 2How many calories does it take to reach childhood obesity prevention goals? 3Loyola study debunks common myth that urine is sterile 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: